Collplant Biotechnologies Ltd (CLGN) Inventory Turnover Ratio, from fourth quarter 2025 to fourth quarter 2024, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 
Collplant Biotechnologies Ltd  (NASDAQ: CLGN)
 

Collplant Biotechnologies Ltd Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Collplant Biotechnologies Ltd inventory turnover ratio, the Collplant Biotechnologies Ltd's ability to sell and replace its inventory in the fourth quarter 2025, sequentially increased to 2.12 in the fourth quarter 2025, CLGN's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Collplant Biotechnologies Ltd in Dec 31 2025 quarter, has decreased to 172 days, compare to 227 days, in the 0 quarter.

Within Healthcare sector 250 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form in the third quarter 2025, to 1753.

CLGN Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Collplant Biotechnologies Ltd Market Share?

What is Inventory Turnover Ratio?




CLGN Inventory Turnover Ratio (Dec 31 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2024)
II. Quarter
Y / Y Inventory Growth 88.31 % 159.28 % -8.69 % -19.75 % -82.3 %
Y / Y Cost of Sales Growth 55.78 % - - - -
Inventory Turnover Ratio (TTM) 2.12 - 7.53 - 7.71
CLGN's Total Ranking # 1753 # # # #
Average inventory processing period 172 - 49 - 47
Seq. Inventory Growth -49.39 % 15.99 % -13.79 % 272.08 % -30.32 %
Seq. Cost of Sales Growth - - - - -73.08 %




Inventory Turnover Ratio Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 251
Overall Market # 1753

Inventory Turnover Ratio Statistics
High Average Low
2.79 1.59 0.28
(Dec 31 2023)   (Dec 31 2022)




Financial Statements
Collplant Biotechnologies Ltd's Inventories $ 0 Millions Visit CLGN's Balance sheet
Collplant Biotechnologies Ltd's Cost of Revenues TTM $ 1 Millions Visit CLGN's Income Statement
What are CLGN's Sales? Visit CLGN's Sales by Segment

Other Inventory Turnover Ratios
Collplant Biotechnologies Ltd's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Medical Equipment & Supplies Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
CLGN's Inventory Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for CLGN's Competitors
Inventory Turnover Ratio for CLGN's Suppliers
Inventory Turnover Ratio for CLGN's Customers

You may also want to know
CLGN's Sales Growth Rates CLGN's Pe Price to earnings ratio CLGN's Receivables Turnover Ratio CLGN's Stock Quote
CLGN's Net Income Growth Rates CLGN's Ps Price to Sales ratio CLGN's Sales per Employee CLGN's Asset Turnover Ratio
CLGN's Net Margin CLGN's Pb Price to Book ratio CLGN's Financial Strength Ratios CLGN's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Dec 31 2025 Inventories at quarter ending Dec 31 2025
Nano X Imaging Ltd  9.44 $ 25.809  Millions$ 3  Millions
Concord Medical Services Holdings Ltd  9.43 $ 62.160  Millions$ 7  Millions
Lantheus Holdings Inc   9.29 $ 599.000  Millions$ 64  Millions
Carlsmed Inc   9.23 $ 12.110  Millions$ 1  Millions
National Vision Holdings Inc   9.22 $ 819.469  Millions$ 89  Millions
Sotera Health Company  9.20 $ 518.000  Millions$ 56  Millions
Alnylam Pharmaceuticals Inc   9.17 $ 677.166  Millions$ 74  Millions
Tarsus Pharmaceuticals Inc   9.11 $ 33.679  Millions$ 4  Millions
Warby Parker Inc   8.81 $ 401.000  Millions$ 45  Millions
Lifemd Inc   8.69 $ 27.000  Millions$ 3  Millions
Castle Biosciences Inc   8.33 $ 71.028  Millions$ 9  Millions
Myriad Genetics Inc   8.29 $ 247.000  Millions$ 30  Millions
Cardiff Lexington Corporation  8.23 $ 4.442  Millions$ 1  Millions
Collegium Pharmaceutical Inc   8.19 $ 316.071  Millions$ 39  Millions
Charles River Laboratories International inc   7.90 $ 2,314.760  Millions$ 293  Millions
Pulse Biosciences Inc   7.87 $ 0.539  Millions$ 0  Millions
Adaptive Biotechnologies Corporation  7.75 $ 71.359  Millions$ 9  Millions
Inogen Inc   7.65 $ 194.403  Millions$ 25  Millions
Casi Pharmaceuticals inc   7.55 $ 10.636  Millions$ 1  Millions
Puma Biotechnology Inc   7.19 $ 58.157  Millions$ 8  Millions
Fonar Corporation  7.19 $ 19.805  Millions$ 3  Millions
Twist Bioscience Corporation  7.01 $ 189.423  Millions$ 27  Millions
Bellevue Life Sciences Acquisition Corp  6.84 $ 2.252  Millions$ 0  Millions
Carlisle Companies Incorporated  6.59 $ 3,227.300  Millions$ 490  Millions
Vanda Pharmaceuticals Inc   6.53 $ 13.044  Millions$ 2  Millions
Novavax inc   6.41 $ 73.040  Millions$ 11  Millions
Opko Health Inc   6.14 $ 400.939  Millions$ 65  Millions
Hims and Hers Health Inc   6.08 $ 614.000  Millions$ 101  Millions
Kewaunee Scientific Corporation  6.02 $ 205.000  Millions$ 34  Millions
Bionexus Gene Lab Corp   6.01 $ 6.124  Millions$ 1  Millions

Date modified: 2026-09-04T17:23:06+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.